IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Br J Haematol. 2013 Aug;162(4):465-73. doi: 10.1111/bjh.12409. Epub 2013 Jun 29.
An increased number of circulating monocytes at presentation has recently been associated with shorter survival in Hodgkin lymphoma, follicular lymphoma and diffuse large B cell lymphoma. This study aimed to assess the prognostic impact of the absolute monocyte count (AMC) at diagnosis in mantle cell lymphoma (MCL). AMC at diagnosis was available in 97 MCL cases recorded in the databases of the Oncology Institute of Southern Switzerland in Bellinzona (Switzerland) and the Division of Haematology of the Amedeo Avogadro University of Eastern Piedmont in Novara (Italy). With a median follow up of 7 years, the 5-year overall survival was 29% for patients with AMC >0·50 × 10(9) /l and 62% for patients with AMC ≤0·50 × 10(9) /l (P = 0·008). Elevated AMC and beta-2 microglobulin at diagnosis remained independent outcome predictors at multivariate analysis, controlling for the MCL International Prognostic Index (MIPI), and have been used to build a simple prognostic scoring system. In this relatively small and heterogeneous series an increased AMC identified poor-risk patients. Our results suggest that AMC together with the beta-2 microglobulin level might provide an inexpensive way to stratify MCL patient risk as a complement to the MIPI, which was confirmed to be a very powerful prognostic tool.
目前，循环单核细胞数量的增加与霍奇金淋巴瘤、滤泡性淋巴瘤和弥漫性大 B 细胞淋巴瘤的生存时间缩短有关。本研究旨在评估绝对单核细胞计数（AMC）在套细胞淋巴瘤（MCL）诊断时的预后影响。在瑞士贝林佐纳南方肿瘤研究所（瑞士）和意大利诺瓦拉 Amedeo Avogadro 大学血液科的数据库中记录了 97 例 MCL 病例，这些病例均有 AMC 诊断值。中位随访 7 年后，AMC＞0.50×10(9)/l 的患者 5 年总生存率为 29%，而 AMC≤0.50×10(9)/l 的患者为 62%（P=0.008）。在多变量分析中，诊断时升高的 AMC 和β-2 微球蛋白仍然是独立的预后预测因素，可控制 MCL 国际预后指数（MIPI），并已用于构建简单的预后评分系统。在这项相对较小且异质性的研究中，增加的 AMC 确定了高危患者。我们的结果表明，AMC 联合β-2 微球蛋白水平可能提供一种经济有效的方法来分层 MCL 患者的风险，补充 MIPI，MIPI 被证实是一种非常强大的预后工具。
